Observe Medical Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Observe Medical şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-31.8%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-31.8%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: OBSRV şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: OBSRV şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Observe Medical Piyasaya Karşı Temettü Getirisi

OBSRV temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (OBSRV)	n/a
Pazarın Alt %25'i (NO)	3.4%
Pazarın En İyi %25'i (NO)	7.6%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (OBSRV) (3 yıla kadar)	n/a

Önemli Temettü: OBSRV şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, OBSRV şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: OBSRV şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: OBSRV herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Observe Medical Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New major risk - Share price stability

First half 2024 earnings released: kr0.12 loss per share (vs kr0.66 loss in 1H 2023)

Observe Medical ASA Appoints Jørgen Mann as Permanent CEO

Is Observe Medical (OB:OBSRV) Using Too Much Debt?

Observe Medical Asa Announces CFO Changes

Full year 2023 earnings released: kr1.05 loss per share (vs kr1.08 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Chief Financial Officer exercised options to buy kr149k worth of stock.

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 35.670322 million.

Observe Medical ASA to Report First Half, 2024 Results on Aug 30, 2024

Observe Medical ASA (OB:OBSRV) signed a letter of intent to acquire UnoMeter portfolio of Nordic distributor Vingmed from Vingmed AS.

Observe Medical ASA has filed a Follow-on Equity Offering in the amount of NOK 55 million.

Observe Medical ASA announced that it has received NOK 7.25 million in funding

Second quarter 2023 earnings released: kr0.33 loss per share (vs kr0.15 loss in 2Q 2022)

New major risk - Share price stability

Full year 2022 earnings released: kr1.08 loss per share (vs kr1.34 loss in FY 2021)

Observe Medical ASA Appoints Jørgen Mann as Chief Commercial Officer

Observe Medical ASA to Report Fiscal Year 2022 Final Results on Apr 28, 2023

Observe Medical ASA to Report First Half, 2023 Results on Aug 25, 2023

No independent directors

Third quarter 2022 earnings released: kr0.28 loss per share (vs kr0.43 loss in 3Q 2021)

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Observe Medical ASA Appoints Carsten Trygve Bøgh as Chief Technology Officer, Effective 2 October 2022

Second quarter 2022 earnings released: kr0.15 loss per share (vs kr0.068 profit in 2Q 2021)

Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way?

Observe Medical ASA Announces Executive Appointments

First quarter 2022 earnings released: kr0.46 loss per share (vs kr0.25 loss in 1Q 2021)

Observe Medical ASA to Report Q1, 2022 Results on Jun 03, 2022

No independent directors

Full year 2021 earnings released: kr1.34 loss per share (vs kr2.22 loss in FY 2020)

Observe Medical ASA Announces Executive Changes

Observe Medical ASA (OB:OBSRV) completed the acquisition of Biim Ultrasound AS.

Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt

Observe Medical ASA to Report Q4, 2022 Results on Mar 29, 2022

We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt

First quarter 2021 earnings released

Nya Karolinska Sjukhuset Initiates New Studies to Broaden the Clinical Scope of Use for Sippi

Observe Medical Asa Announces an Order to Deliver Newly Introduced Blood & Fluid Warmer System, Including Disposable Supplies, to Two University Hospitals and One Regional Hospital in Nordic Market

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Full year 2020 earnings released: kr1.88 loss per share (vs kr1.36 loss in FY 2019)

Observe Medical ASA announces Nya Karolinska Sjukhuset in Sweden Resumes the Implementation of Sippi® in Clinical Use At Cardiothoracic ICU Unit

New 90-day high: kr29.80

Observe Medical Asa Announces Hospital in Northern Italy Has Equipped the Icu Department with Sippi® Systems in Clinical Use

Observe Medical ASA Announces Collaborations with the Norwegian Medtech Agency and Yallow Life Science AS

New 90-day high: kr16.00

Observe Medical Receives Significant Order for Medical Consumables from A Hospital Region in the Nordic Market

Observe Medical ASA Announces Doctoral Dissertation Further Demonstrates Clinical Benefits of Sippi®

New 90-day high: kr14.70

Observe Medical ASA Appoints Anders Nachtweij as New Head of Sales

New 90-day low: kr11.40

New 90-day low: kr11.90

Observe Medical ASA (OB:OBSERV) completed the acquisition of Sylak AB from ABIGO Medical AB.

New 90-day low: kr12.00

Observe Medical ASA (OB:OBSERV) signed a non-binding term sheet Sylak AB from ABIGO Medical AB for SEK 6 million.

New 90-day low: kr13.20

Earnings released

Observe Medical ASA to Report Q1, 2021 Results on May 12, 2021

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 44.999999 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin